Syndax Non Currrent Assets Other from 2010 to 2025
| SNDX Stock | USD 13.56 0.43 3.27% |
Non Currrent Assets Other | First Reported 2012-12-31 | Previous Quarter 217 K | Current Value 217 K | Quarterly Volatility 2.5 M |
Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.6 K, Interest Expense of 5.2 M or Selling General Administrative of 126.9 M, as well as many indicators such as Price To Sales Ratio of 52.11, Dividend Yield of 0.0198 or PTB Ratio of 4.12. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
Syndax | Non Currrent Assets Other |
Latest Syndax Pharmaceuticals' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Syndax Pharmaceuticals over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Syndax Pharmaceuticals' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
Syndax Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 1,271,197 | |
| Geometric Mean | 589,745 | |
| Coefficient Of Variation | 178.75 | |
| Mean Deviation | 1,238,551 | |
| Median | 755,000 | |
| Standard Deviation | 2,272,206 | |
| Sample Variance | 5.2T | |
| Range | 9.4M | |
| R-Value | 0.15 | |
| Mean Square Error | 5.4T | |
| R-Squared | 0.02 | |
| Significance | 0.59 | |
| Slope | 69,590 | |
| Total Sum of Squares | 77.4T |
Syndax Non Currrent Assets Other History
About Syndax Pharmaceuticals Financial Statements
Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 217 K | 206.2 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.